Yen MT, Cockerham K, Saeed P, et al. THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease. Ophthalmology. Published online June 1, 2026. doi:10.1016/j.ophtha.2026.04.022. View article
Abrams, J.G., Gustafson, C., Danese, S.R. et al. Impacts of Thyroid Eye Disease (TED), Beyond the Signs and Symptoms: Results from the ElevaTED Patient Survey. Ophthalmol Ther (2026). doi: 10.1007/s40123-026-01393-2. View article
Kaplan R, Zhao Y, Tsai J, et al. Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease. MAbs. 2025;17(1):2585616. doi:10.1080/19420862.2025.2585616. View article